Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives ; volume:80 ; number:12 ; day:15 ; month:7 ; year:2020 ; pages:1203-1210 ; date:8.2020
Drugs ; 80, Heft 12 (15.7.2020), 1203-1210, 8.2020
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-020-01361-5
- URN
-
urn:nbn:de:101:1-2020092800095004549862
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Trojan, Jörg
- SpringerLink (Online service)
Other Objects (12)
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Anti-angiogenesis in hepatocellular carcinoma treatment : current evidence and future perspectives
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
Anti-angiogenesis in hepatocellular carcinoma treatment : current evidence and future perspectives
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
Cabozantinib : Cabozantinib in der Behandlung des fortgeschrittenen Nierenzellkarzinoms
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States